抑制JAK-STAT通路可纠正舍格伦病患者的唾液腺炎症及干扰素驱动的免疫激活
本研究对人类小唾液腺(MSG)和外周血单个核细胞(PBMC)进行转录组测序、免疫荧光及流式分析,发现舍格伦病(SjD)患者JAK-STAT通路激活且干扰素刺激基因(ISG)表达升高,JAK抑制剂(JAKi)可在体外纠正该异常信号且无细胞毒性。作者据此认为JAKi是潜在的SjD治疗选择,并已启动托法替布治疗SjD的Ib/IIa期随机对照试验。
要点
- SjD患者小唾液腺中JAK-STAT通路激活,ISG表达升高并与聚焦评分、抗SSA阳性等临床变量相关。
- 单细胞测序显示MSG细胞类型特异性上调JAK-STAT和ISG,PBMC中单核细胞ISG明显上调。
- 体外JAKi可纠正SjD MSG、PBMC升高的基础pSTAT水平及pSGEC对IFN-β的过度反应,且无细胞毒性。
核心结论
- SjD患者组织以细胞类型依赖方式呈现ISG表达增加和JAK-STAT通路激活。
- JAKi在组织层面和PBMC中可正常化该异常信号,作者认为其是靶向腺体及腺外症状的潜在可行疗法。
- 基于上述数据,已启动托法替布治疗SjD的Ib/IIa期随机对照试验。
研究设计与样本
- 对人小唾液腺(MSG)和外周血单个核细胞(PBMC)进行bulk或单细胞RNA测序、免疫荧光显微镜和流式细胞术检测。
- 对PBMC和原代唾液腺上皮细胞(pSGEC)系进行离体培养试验,模拟JAKi前后靶组织的变化。
主要发现
- RNAseq和免疫荧光显示SjD MSG中JAK-STAT通路激活。
- ISG表达升高与临床变量(如聚焦评分、抗SSA阳性)相关。
- MSG单细胞RNAseq显示细胞类型特异性JAK-STAT和ISG上调;PBMC呈相似趋势,包括单核细胞ISG明显上调。
- 离体研究显示SjD MSG和PBMC基础pSTAT水平升高,JAKi可纠正。
- SjD来源pSGEC基础ISG表达更高、对IFN-β反应过度,JAKi可使其正常化且无细胞毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Inflammatory cytokines that signal through the Janus kinases-signal transducer and activator of transcription (JAK-STAT) pathway, especially interferons (IFNs), are implicated in Sjögren's disease (SjD). Although inhibition of JAKs is effective in other autoimmune diseases, a systematic investigation of IFN-JAK-STAT signalling and the effect of JAK inhibitor (JAKi) therapy in SjD-affected human tissues has not been fully investigated. METHODS: Human minor salivary glands (MSGs) and peripheral blood mononuclear cells (PBMCs) were investigated using bulk or single-cell (sc) RNA sequencing (RNAseq), immunofluorescence (IF) microscopy and flow cytometry. Ex vivo culture assays on PBMCs and primary salivary gland epithelial cell (pSGEC) lines were performed to model changes in target tissues before and after JAKi. RESULTS: RNAseq and IF showed activated JAK-STAT pathway in SjD MSGs. Elevated IFN-stimulated gene (ISGs) expression associated with clinical variables (eg, focus scores, anti-SSA positivity). scRNAseq of MSGs exhibited cell type-specific upregulation of JAK-STAT and ISGs; PBMCs showed similar trends, including markedly upregulated ISGs in monocytes. Ex vivo studies showed elevated basal pSTAT levels in SjD MSGs and PBMCs that were corrected with JAKi. SjD-derived pSGECs exhibited higher basal ISG expressions and exaggerated responses to IFN-β, which were normalised by JAKi without cytotoxicity. CONCLUSIONS: SjD patients' tissues exhibit increased expression of ISGs and activation of the JAK-STAT pathway in a cell type-dependent manner. JAKi normalises this aberrant signalling at the tissue level and in PBMCs, suggesting a putative viable therapy for SjD, targeting both glandular and extraglandular symptoms. Predicated on these data, a phase Ib/IIa randomised controlled trial to treat SjD with tofacitinib was initiated.
引用
- Gupta S, Yamada E, Nakamura H, et al. Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren's disease. Ann Rheum Dis. 2024. PMID: 38527764. doi:10.1136/ard-2023-224842
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。